prmedПервичная медико-санитарная помощьPrimary Health Care (Russian Federation)3034-41233034-4565LTD "Silicea-Poligraf"10.15829/3034-4123-2024-24IXJDOKprmed-24Research ArticleМЕТОДИЧЕСКИЕ РЕКОМЕНДАЦИИGUIDELINESДиспансерное наблюдение пациентов с фибрилляцией и трепетанием предсердий врачом-терапевтом в первичном звене здравоохранения. Методические рекомендацииOutpatient follow-up of patients with atrial fibrillation and flutter by a primary care physician. GuidelinesДрапкинаО. М.DrapkinaO. M.

Д.м.н., профессор, академик РАН, директор ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России, зав. кафедрой терапии и профилактической медицины ФГБОУ ВО "Российский университет медицины" Минздрава России

Москва

Moscow

cardio.nauka@yandex.ruБойцовС. А.BoytsovS. A.

Д.м.н., профессор, академик РАН, генеральный директор ФГБУ "НМИЦ кардиологии им. акад. Е. И. Чазова" Минздрава России, профессор кафедры поликлинической терапии поликлинической терапии ФГБОУ ВО "Российский университет медицины" Минздрава России

Москва

Moscow

ГолуховаЕ. З.GolukhovaE. Z.

Д.м.н., профессор, академик РАН, директор ФГБУ "Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А. Н. Бакулева" Минздрава России

Москва

Moscow

ДавтянК. В.DavtyanK. V.

Д.м.н., профессор, руководитель отдела нарушений сердечного ритма и проводимости ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России

Москва

Moscow

ДроздоваЛ. Ю.DrozdovaL. Yu.

К.м.н., руководитель лаборатории поликлинической терапии ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России

Москва

Moscow

ИпатовП. В.IpatovP. V.

Д.м.н., профессор, главный научный сотрудник ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России

Москва

Moscow

КалининаА. М.KalininaA. M.

Д.м.н., профессор, руководитель отдела первичной профилактики хронических неинфекционных заболеваний в системе здравоохранения ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России

Москва

Moscow

МарцевичС. Ю.MartsevichS. Yu.

Д.м.н., профессор, руководитель отдела профилактической фармакотерапии, главный научный сотрудник ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России

Москва

Moscow

СавченкоЕ. Д.SavchenkoE. D.

К.м.н., ведущий научный сотрудник отдела научно-стратегического развития первичной медико-санитарной помощи, доцент кафедры общественного здоровья и здравоохранения Института профессионального образования и аккредитации ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России

Москва

Moscow

ХарлапМ. С.KharlapM. S.

К.м.н., ведущий научный сотрудник отдела нарушений сердечного ритма и проводимости ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России

Москва

Moscow

ШепельР. Н.ShepelR. N.

К.м.н., зам. директора по перспективному развитию медицинской деятельности, руководитель отдела научно-стратегического развития первичной медико-санитарной помощи, ведущий научный сотрудник отдела научно-стратегического развития первичной медикосанитарной помощи, доцент кафедры общественного здоровья и организации здравоохранения ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России, доцент кафедры терапии и профилактической медицины ФГБОУ ВО "Российский университет медицины" Минздрава России

Москва

Moscow

r.n.shepel@mail.ruЯвеловИ. С.YavelovI. S.

Д.м.н., профессор, руководитель отдела фундаментальных и клинических проблем тромбоза при неинфекционных заболеваниях ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России

Москва

Moscow

ЖамаловЛ. М.ZhamalovL. M.

Врач-методист группы по организации медицинской помощи отдела организационно-методического управления и анализа оказания медицинской помощи ФГБУ "Национальный медицинский центр терапии и профилактической медицины" Минздрава России

Москва

Moscow

ФГБУ "НМИЦ ТПМ" Минздрава России; ФГБУ "НМИЦК им. акад Е. И. Чазова" Минздрава России; ФГБУ "НМИЦ ССХ им. А. Н. Бакулева" Минздрава России; Российское общество профилактики неинфекционных заболеванийРоссияNational Medical Research Center for Therapy and Preventive Medicine; E. I. Chazov National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation; A. N. Bakulev Scientific Center of Cardiovascular Surgery of the Ministry of Health of the Russian Federation; Russian University of MedicineRussian Federation20242210202411134178Copyright © Драпкина О.М., Бойцов С.А., Голухова Е.З., Давтян К.В., Дроздова Л.Ю., Ипатов П.В., Калинина А.М., Марцевич С.Ю., Савченко Е.Д., Харлап М.С., Шепель Р.Н., Явелов И.С., Жамалов Л.М., 20242024Драпкина О.М., Бойцов С.А., Голухова Е.З., Давтян К.В., Дроздова Л.Ю., Ипатов П.В., Калинина А.М., Марцевич С.Ю., Савченко Е.Д., Харлап М.С., Шепель Р.Н., Явелов И.С., Жамалов Л.М.Drapkina O.M., Boytsov S.A., Golukhova E.Z., Davtyan K.V., Drozdova L.Y., Ipatov P.V., Kalinina A.M., Martsevich S.Y., Savchenko E.D., Kharlap M.S., Shepel R.N., Yavelov I.S., Zhamalov L.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://prmed.elpub.ru/jour/article/view/24

Методические рекомендации содержат описание организации проведения диспансерного наблюдения пациентов с фибрилляцией и трепетанием предсердий врачом-терапевтом, ориентировочный объем и частоту выполнения лабораторно-инструментальных исследований, сведения о диагностике и лечении заболевания, профилактике осложнений.

Методические рекомендации предназначены для врачей-терапевтов участковых, врачей общей практики (семейных врачей), врачей-терапевтов участковых цехового врачебного участка, а также для среднего медицинского персонала, работающего с указанными врачами, для фельдшеров фельдшерско-акушерских пунктов (фельдшерских здравпунктов) в случае возложения на них функций лечащего врача. Методические рекомендации могут быть использованы врачами-организаторами здравоохранения, руководителями медицинских организаций первичной медико-санитарной помощи и их подразделений.

The guidelines contain a description of providing outpatient follow-up of patients with atrial fibrillation and flutter by a general practitioner, the approximate volume and frequency of paraclinical studies, information on the diagnosis and treatment of the disease, and the prevention of complications.

The guidelines are intended for district primary care physicians, general practitioners (family doctors), as well as for the nursing staff, for paramedics of the rural health posts if they are assigned the attending physician functions. The guidelines can be used by health professionals, heads of primary healthcare facilities and their divisions.

методические рекомендациидиспансерное наблюдениефибрилляция предсердийтрепетание предсердийпрофилактикадиспансеризацияпрофилактический осмотрguidelinesoutpatient follow-upatrial fibrillationatrial flutterpreventionpreventive examinationReferencesБойцов С.А., Карпов Ю.А. Клиническая фармакология лекарственных средств для лечения заболеваний сердца и сосудов под редакцией. ГЭОТАРМедиа: 2024; 720 с. ISBN: 978-5-4235-0397.Boytsov SA, Karpov YuA. Clinical pharmacology of medicines for the treatment of heart and vascular diseases edited. GEOTAR Media: 2024; 720 p. (In Russ.) ISBN: 978-5-4235-0397.Нарушения ритма сердца Глава 33 из "Рациональная фармакотерапия сердечно-сосудистых заболеваний: Руководство" Под общей редакцией Е.И. Чазова, Ю.А. Карпова. 2014. сc. 450-515.Cardiac arrhythmias Chapter 33 of "Rational pharmacotherapy of cardiovascular diseases: A guide" Under the general editorship of E.I. Chazov, Yu.A. Karpov. 2014. pp. 450-515. (In Russ.)Аракелян М. Г., Бокерия Л.А., Васильева Е.Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/1560-4071-2021-4594.Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.) doi:10.15829/1560-4071-2021-4594.Peinado R, Arribas F, Ormaetxe JM, Badía X. Variation in quality of life with type of atrial fibrillation. Rev Esp Cardiol. 2010;63(12):1402-9. English, Spanish. doi:10.1016/s1885-5857(10)70274-7.Peinado R, Arribas F, Ormaetxe JM, Badía X. Variation in quality of life with type of atrial fibrillation. Rev Esp Cardiol. 2010;63(12):1402-9. English, Spanish. doi:10.1016/s1885-5857(10)70274-7.Steinberg BA, Kim S, Fonarow GC, et al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014;167(5):735-42.e2. doi:10.1016/j.ahj.2014.02.003.Steinberg BA, Kim S, Fonarow GC, et al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014;167(5):735-42.e2. doi:10.1016/j.ahj.2014.02.003.Benjamin EJ, Muntner P, Alonso A, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. doi:10.1161/CIR.0000000000000659.Benjamin EJ, Muntner P, Alonso A, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. doi:10.1161/CIR.0000000000000659.Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-25. doi:10.1161/CIRCULATIONAHA.105.595140.Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-25. doi:10.1161/CIRCULATIONAHA.105.595140.Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949-53. doi:10.1093/eurheartj/ehi825.Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949-53. doi:10.1093/eurheartj/ehi825.Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534-9. doi:10.1016/j.amjcard.2009.07.022.Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534-9. doi:10.1016/j.amjcard.2009.07.022.Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86(5):516- 21. doi:10.1136/heart.86.5.516.Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86(5):516- 21. doi:10.1136/heart.86.5.516.Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-5. doi:10.1001/jama.285.18.2370.Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-5. doi:10.1001/jama.285.18.2370.Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042-6. doi:10.1161/01.CIR.0000140263.20897.42.Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042-6. doi:10.1161/01.CIR.0000140263.20897.42.Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342(13):913-20. doi:10.1056/NEJM200003303421302.Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342(13):913-20. doi:10.1056/NEJM200003303421302.Asad ZUA, Yousif A, Khan MS, et al. Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circ Arrhythm Electrophysiol. 2019;12(9):e007414. doi:10.1161/CIRCEP.119.007414.Asad ZUA, Yousif A, Khan MS, et al. Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circ Arrhythm Electrophysiol. 2019;12(9):e007414. doi:10.1161/CIRCEP.119.007414.Напалков Д.А., Соколова А.А., Габитова М.А. и др. Прямые оральные антикоагулянты. АБВ-Пресс: Москва; 2019. 96 с.Napalkov DA, Sokolova AA, Gabitova MA, et al. Direct oral anticoagulants. ABV Press: Moscow; 2019. 96 p. (In Russ.)Antithrombotic therapy in cardiology. Ed. Panchenko EP. M.: Remedium Group, 2019. p. 256. (In Russ.) Антитромботическая терапия в кардиологии. Под ред. Панченко Е.П. М.: ООО "Группа Ремедиум", 2019. с. 256. ISBN: 978-5-906499-592.Antithrombotic therapy in cardiology. Ed. Panchenko EP. M.: Remedium Group, 2019. p. 256. (In Russ.) Антитромботическая терапия в кардиологии. Под ред. Панченко Е.П. М.: ООО "Группа Ремедиум", 2019. с. 256. ISBN: 978-5-906499-592.Скирденко Ю.П., Николаев Н.А. Новые подходы к индивидуализированному выбору пероральных антикоагулянтов у больных фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии. 2018;14(1):58-64. doi:10.20996/1819-6446-2018-14-1-58-64.Skirdenko JP, Nikolayev NA. New approaches to individualized choice of oral anticoagulants in patients with atrial fibrillation. Rational Pharmacotherapy in Cardiology. 2018;14(1):58-64. (In Russ.) doi:10.20996/1819-6446-2018-14-1-58-64.Urquhart J, Eisen G, Faigel DO, et al. A closer look at same-day bidirectional endoscopy. Gastrointest Endosc. 2009;69(2):271-7. doi:10.1016/j.gie.2008.04.063.Urquhart J, Eisen G, Faigel DO, et al. A closer look at same-day bidirectional endoscopy. Gastrointest Endosc. 2009;69(2):271-7. doi:10.1016/j.gie.2008.04.063.Rockey DC, Koch J, Cello JP, et al. Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests. N Engl J Med. 1998;339(3):153-9. doi:10.1056/NEJM199807163390303.Rockey DC, Koch J, Cello JP, et al. Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests. N Engl J Med. 1998;339(3):153-9. doi:10.1056/NEJM199807163390303.Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713-9. doi:10.1016/j.ahj.2005.04.017.Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713-9. doi:10.1016/j.ahj.2005.04.017.Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013;34(14):1061-7. doi:10.1093/eurheartj/ehs469.Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013;34(14):1061-7. doi:10.1093/eurheartj/ehs469.Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/ Paisley study. Am J Med. 2002;113(5):359-64. doi:10.1016/s0002-9343(02)01236-6.Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/ Paisley study. Am J Med. 2002;113(5):359-64. doi:10.1016/s0002-9343(02)01236-6.Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-52. doi:10.1161/01.cir.98.10.946.Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-52. doi:10.1161/01.cir.98.10.946.Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-8. doi:10.1161/01.str.22.8.983.Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-8. doi:10.1161/01.str.22.8.983.Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98(5):476-84. doi:10.1016/S0002-9343(99)80348-9.Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98(5):476-84. doi:10.1016/S0002-9343(99)80348-9.Kotecha D, Holmes J, Krum H, et al. Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235-43. doi:10.1016/S0140-6736(14)61373-8.Kotecha D, Holmes J, Krum H, et al. Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235-43. doi:10.1016/S0140-6736(14)61373-8.Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke. 2013;44(12):3357-64. doi:10.1161/STROKEAHA.113.001884.Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke. 2013;44(12):3357-64. doi:10.1161/STROKEAHA.113.001884.Henriksson KM, Farahmand B, Åsberg S, Edvardsson N et al. Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. Int J Stroke. 2012;7(4):276-81. doi:10.1111/j.1747-4949.2011.00706.x.Henriksson KM, Farahmand B, Åsberg S, Edvardsson N et al. Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. Int J Stroke. 2012;7(4):276-81. doi:10.1111/j.1747-4949.2011.00706.x.Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45(2):520-6. doi:10.1161/STROKEAHA.113.003433.Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45(2):520-6. doi:10.1161/STROKEAHA.113.003433.Kirchhof P, Schmalowsky J, Pittrow D, et al. ATRIUM Study Group. Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry. Clin Cardiol. 2014;37(5):277-84. doi:10.1002/clc.22272.Kirchhof P, Schmalowsky J, Pittrow D, et al. ATRIUM Study Group. Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry. Clin Cardiol. 2014;37(5):277-84. doi:10.1002/clc.22272.Ulimoen SR, Enger S, Carlson J, et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol. 2013;111(2):225-30. doi:10.1016/j.amjcard.2012.09.020.Ulimoen SR, Enger S, Carlson J, et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol. 2013;111(2):225-30. doi:10.1016/j.amjcard.2012.09.020.Scheuermeyer FX, Grafstein E, Stenstrom R, et al. Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med. 2013;20(3):222-30. doi:10.1111/acem.12091.Scheuermeyer FX, Grafstein E, Stenstrom R, et al. Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med. 2013;20(3):222-30. doi:10.1111/acem.12091.Tisdale JE, Padhi ID, Goldberg AD, et al. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. Am Heart J. 1998;135:739-47. doi:10.1016/s0002-8703(98)70031-6.Tisdale JE, Padhi ID, Goldberg AD, et al. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. Am Heart J. 1998;135:739-47. doi:10.1016/s0002-8703(98)70031-6.Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33(2):304-10. doi:10.1016/s0735-1097(98)00561-0.Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33(2):304-10. doi:10.1016/s0735-1097(98)00561-0.Groenveld HF, Tijssen JG, Crijns HJ, et al. RACE II Investigators. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol. 2013;61(7):741-8. doi:10.1016/j.jacc.2012.11.038.Groenveld HF, Tijssen JG, Crijns HJ, et al. RACE II Investigators. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol. 2013;61(7):741-8. doi:10.1016/j.jacc.2012.11.038.David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol. 1979;44(7):1378-82. doi:10.1016/0002-9149(79)90456-9.David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol. 1979;44(7):1378-82. doi:10.1016/0002-9149(79)90456-9.Roth A, Harrison E, Mitani G, et al. Efficacy and safety of medium- and highdose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation. 1986;73(2):316-24. doi:10.1161/01.cir.73.2.316.Roth A, Harrison E, Mitani G, et al. Efficacy and safety of medium- and highdose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation. 1986;73(2):316-24. doi:10.1161/01.cir.73.2.316.Nergårdh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study. Eur Heart J. 2007;28(11):1351-7. doi:10.1093/eurheartj/ehl544.Nergårdh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study. Eur Heart J. 2007;28(11):1351-7. doi:10.1093/eurheartj/ehl544.Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451. doi:10.1136/bmj.h4451.Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451. doi:10.1136/bmj.h4451.Allen LA, Fonarow GC, Simon DN, et al. ORBIT-AF Investigators. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015;65(25):2691-8. doi:10.1016/j.jacc.2015.04.045.Allen LA, Fonarow GC, Simon DN, et al. ORBIT-AF Investigators. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015;65(25):2691-8. doi:10.1016/j.jacc.2015.04.045.Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J. 2009;85(1004):303-12. doi:10.1136/pgmj.2008.068908.Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J. 2009;85(1004):303-12. doi:10.1136/pgmj.2008.068908.Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural heart disease. Circulation. 2012;125(7):945-57. doi:10.1161/CIRCULATIONAHA.111.019935.Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural heart disease. Circulation. 2012;125(7):945-57. doi:10.1161/CIRCULATIONAHA.111.019935.Mulder BA, Van Veldhuisen DJ, Crijns HJ, et al. RACE II Investigators. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014;11(9):1543-50. doi:10.1016/j.hrthm.2014.06.007.Mulder BA, Van Veldhuisen DJ, Crijns HJ, et al. RACE II Investigators. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014;11(9):1543-50. doi:10.1016/j.hrthm.2014.06.007.Yu HT, Yang PS, Lee H, et al. Outcomes of Rate-Control Treatment in Patients With Atrial Fibrillation and Heart Failure — A Nationwide Cohort Study. Circ J. 2018;82(3):652-658. doi:10.1253/circj.CJ-17-0669.Yu HT, Yang PS, Lee H, et al. Outcomes of Rate-Control Treatment in Patients With Atrial Fibrillation and Heart Failure — A Nationwide Cohort Study. Circ J. 2018;82(3):652-658. doi:10.1253/circj.CJ-17-0669.Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol. 1998;81(5):594-8. doi:10.1016/s0002-9149(97)00962-4.Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol. 1998;81(5):594-8. doi:10.1016/s0002-9149(97)00962-4.Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001;29(6):1149-53. doi:10.1097/00003246-200106000-00011.Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001;29(6):1149-53. doi:10.1097/00003246-200106000-00011.Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J. 1995;16(4):521-8. doi:10.1093/oxfordjournals.eurheartj.a060945.Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J. 1995;16(4):521-8. doi:10.1093/oxfordjournals.eurheartj.a060945.Tse HF, Lam YM, Lau CP, et al. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol. 2001;28(5-6):446-50. doi:10.1046/j.1440-1681.2001.03454.x.Tse HF, Lam YM, Lau CP, et al. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol. 2001;28(5-6):446-50. doi:10.1046/j.1440-1681.2001.03454.x.Ecker V, Knoery C, Rushworth G, et al. A review of factors associated with maintenance of sinus rhythm after elective electrical cardioversion for atrial fibrillation. Clin Cardiol. 2018;41(6):862-70. doi:10.1002/clc.22931.Ecker V, Knoery C, Rushworth G, et al. A review of factors associated with maintenance of sinus rhythm after elective electrical cardioversion for atrial fibrillation. Clin Cardiol. 2018;41(6):862-70. doi:10.1002/clc.22931.Airaksinen KE, Grönberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013;62(13):1187-92. doi:10.1016/j.jacc.2013.04.089.Airaksinen KE, Grönberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013;62(13):1187-92. doi:10.1016/j.jacc.2013.04.089.Hansen ML, Jepsen RMHG, Olesen JB, et al. Thromboembolic risk in 16274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. EP Eur. 2015;17(1):18-23. doi:10.1093/europace/euu189.Hansen ML, Jepsen RMHG, Olesen JB, et al. Thromboembolic risk in 16274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. EP Eur. 2015;17(1):18-23. doi:10.1093/europace/euu189.Klein AL, Grimm RA, Murray RD, et al. Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19):1411-20. doi:10.1056/NEJM200105103441901.Klein AL, Grimm RA, Murray RD, et al. Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19):1411-20. doi:10.1056/NEJM200105103441901.Hagens VE, Ranchor AV, Van Sonderen E, et al. RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43(2):241-7. doi:10.1016/j.jacc.2003.08.037.Hagens VE, Ranchor AV, Van Sonderen E, et al. RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43(2):241-7. doi:10.1016/j.jacc.2003.08.037.Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, et al. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol. 1999;84(9A):147R-151R. doi:10.1016/s0002-9149(99)00715-8.Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, et al. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol. 1999;84(9A):147R-151R. doi:10.1016/s0002-9149(99)00715-8.Фомина И.Г., Тарзиманова А.И., Ветлужский А.В., Абрамова А.А. Пропафенон при восстановлении и сохранении синусового ритма у больных с персистирующей формой фибрилляции предсердий. "ПРОМЕТЕЙ" — открытое мультицентровое исследование в РФ. Рациональная Фармакотерапия в Кардиологии. 2006;2(1):37-40.Fomina IG, Tarzimanova AI, Vetluzsky AV, Abramova AA. Propafenone for sinus rhythm recovery and support in patients with persistent form of auricular fiblillation. "PROMETHEUS" — opened multicenter study in Russian Federation. Rational Pharmacotherapy in Cardiology. 2006;2(1):37-40. (In Russ.)Тарасов А.В., Косых С.А., Бушуева Е.В. и др. Сравнение эффективности инъекционных форм антиаритмических препаратов пропафенона и амиодарона при проведении фармакологической кардиоверсии пароксизмальной фибрилляции предсердий. Consilium Medicum. 2019;21(1):81-6. doi:10.26442/20751753.2019.1.190286.Tarasov AV, Kosykh SA, Bushueva EV, et al. Comparison of the effectiveness of injectable forms of antiarrhythmic drugs propafenone and amiodarone during pharmacological cardioversion of paroxysmal atrial fibrillation. Consilium Medicum. 2019;21(1):81-6. (In Russ.) doi:10.26442/20751753.2019.1.190286.Pluymaekers NAHA, Dudink EAMP, Luermans JGLM, et al. RACE 7 ACWAS Investigators. Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation. N Engl J Med. 2019;380(16):1499-508. doi:10.1056/NEJMoa1900353.Pluymaekers NAHA, Dudink EAMP, Luermans JGLM, et al. RACE 7 ACWAS Investigators. Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation. N Engl J Med. 2019;380(16):1499-508. doi:10.1056/NEJMoa1900353.Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429. doi:10.1093/eurheartj/ehq278.Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429. doi:10.1093/eurheartj/ehq278.Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1-e88. doi:10.1093/ejcts/ezw313.Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1-e88. doi:10.1093/ejcts/ezw313.Um KJ, McIntyre WF, Healey JS, et al. Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and metaanalysis. Europace. 2019;21(6):856-63. doi:10.1093/europace/euy310.Um KJ, McIntyre WF, Healey JS, et al. Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and metaanalysis. Europace. 2019;21(6):856-63. doi:10.1093/europace/euy310.Singh SN, Tang XC, Reda D, Singh BN. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Heart Rhythm. 2009;6(2):152-5. doi:10.1016/j.hrthm.2008.10.036.Singh SN, Tang XC, Reda D, Singh BN. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Heart Rhythm. 2009;6(2):152-5. doi:10.1016/j.hrthm.2008.10.036.Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72. doi:10.1378/chest.09-1584.Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72. doi:10.1378/chest.09-1584.Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-67. doi:10.7326/0003-4819-146-12-200706190-00007.Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-67. doi:10.7326/0003-4819-146-12-200706190-00007.Joundi RA, Cipriano LE, Sposato LA, Saposnik G; Stroke Outcomes Research Working Group. Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis. Stroke. 2016;47(5):1364-7. doi:10.1161/STROKEAHA.115.012609.Joundi RA, Cipriano LE, Sposato LA, Saposnik G; Stroke Outcomes Research Working Group. Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis. Stroke. 2016;47(5):1364-7. doi:10.1161/STROKEAHA.115.012609.Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA. 2015;313(19):1950-62. doi:10.1001/jama.2015.4369.Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA. 2015;313(19):1950-62. doi:10.1001/jama.2015.4369.Potpara TS, Polovina MM, Licina MM, et al. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012;5(2):319- 26. doi:10.1161/CIRCEP.111.966713.Potpara TS, Polovina MM, Licina MM, et al. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012;5(2):319- 26. doi:10.1161/CIRCEP.111.966713.Chao TF, Liao JN, Tuan TC, et al. Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially ‘Low-Risk’ Patients. Thromb Haemost. 2019;119(7):1162-70. doi:10.1055/s-0039-1683933.Chao TF, Liao JN, Tuan TC, et al. Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially ‘Low-Risk’ Patients. Thromb Haemost. 2019;119(7):1162-70. doi:10.1055/s-0039-1683933.Chao TF, Lip GYH, Lin YJ, Chang SL, et al. Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors. Thromb Haemost. 2018;118(4):768-77. doi:10.1055/s-0038-1636534.Chao TF, Lip GYH, Lin YJ, Chang SL, et al. Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors. Thromb Haemost. 2018;118(4):768-77. doi:10.1055/s-0038-1636534.Rubboli A, Becattini C, Verheugt FW. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol. 2011;3(11):351-8. doi:10.4330/wjc.v3.i11.351.Rubboli A, Becattini C, Verheugt FW. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol. 2011;3(11):351-8. doi:10.4330/wjc.v3.i11.351.Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100. doi:10.1378/chest.10-0134.Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100. doi:10.1378/chest.10-0134.Chang G, Xie Q, Ma L, Hu K, et al. Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: A network meta-analysis. J Thromb Haemost. 2020;18(4):791-801. doi:10.1111/jth.14692.Chang G, Xie Q, Ma L, Hu K, et al. Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: A network meta-analysis. J Thromb Haemost. 2020;18(4):791-801. doi:10.1111/jth.14692.Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost. 2016;14(9):1711-4. doi:10.1111/jth.13386.Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost. 2016;14(9):1711-4. doi:10.1111/jth.13386.Böhm M, Ezekowitz MD, Connolly SJ, et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015;65(23):2481-93. doi:10.1016/j.jacc.2015.03.577.Böhm M, Ezekowitz MD, Connolly SJ, et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015;65(23):2481-93. doi:10.1016/j.jacc.2015.03.577.Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016;1(4):451-60. doi:10.1001/jamacardio.2016.1170.Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016;1(4):451-60. doi:10.1001/jamacardio.2016.1170.Steffel J, Verhamme P, Potpara TS, et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-93. doi:10.1093/eurheartj/ehy136.Steffel J, Verhamme P, Potpara TS, et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-93. doi:10.1093/eurheartj/ehy136.Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. doi:10.1111/bcp.12075.Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. doi:10.1111/bcp.12075.Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drugdrug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448-58. doi:10.1124/dmd.109.029694.Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drugdrug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448-58. doi:10.1124/dmd.109.029694.Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-75. doi:10.1111/j.1538-7836.2011.04498.x.Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-75. doi:10.1111/j.1538-7836.2011.04498.x.Halperin JL, Hankey GJ, Wojdyla DM, et al. ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138-46. doi:10.1161/CIRCULATIONAHA.113.005008.Halperin JL, Hankey GJ, Wojdyla DM, et al. ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138-46. doi:10.1161/CIRCULATIONAHA.113.005008.Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864-72. doi:10.1093/eurheartj/ehu046.Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864-72. doi:10.1093/eurheartj/ehu046.Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72. doi:10.1161/CIRCULATIONAHA.110.004747.Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72. doi:10.1161/CIRCULATIONAHA.110.004747.Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi:10.1056/NEJMoa1107039.Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi:10.1056/NEJMoa1107039.Braekkan SK, van der Graaf Y, Visseren FL, Algra A. Obesity and risk of bleeding: the SMART study. J Thromb Haemost. 2016;14(1):65-72. doi:10.1111/jth.13184.Braekkan SK, van der Graaf Y, Visseren FL, Algra A. Obesity and risk of bleeding: the SMART study. J Thromb Haemost. 2016;14(1):65-72. doi:10.1111/jth.13184.Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018;138(15):1519-29. doi:10.1161/CIRCULATIONAHA.118.035418.Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018;138(15):1519-29. doi:10.1161/CIRCULATIONAHA.118.035418.Stanton BE, Barasch NS, Tellor KB. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacotherapy. 2017;37(4):412-9. doi:10.1002/phar.1905.Stanton BE, Barasch NS, Tellor KB. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacotherapy. 2017;37(4):412-9. doi:10.1002/phar.1905.Weir MR, Ashton V, Moore KT, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. Am Heart J. 2020;223:3-11. doi:10.1016/j.ahj.2020.01.010.Weir MR, Ashton V, Moore KT, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. Am Heart J. 2020;223:3-11. doi:10.1016/j.ahj.2020.01.010.Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89-98. doi:10.1111/bcp.12054.Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89-98. doi:10.1111/bcp.12054.Intagliata NM, Henry ZH, Maitland H, et al. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci. 2016;61(6):1721-7. doi:10.1007/s10620-015-4012-2.Intagliata NM, Henry ZH, Maitland H, et al. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci. 2016;61(6):1721-7. doi:10.1007/s10620-015-4012-2.Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017;98(4):393-7. doi:10.1111/ejh.12844.Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017;98(4):393-7. doi:10.1111/ejh.12844.De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis — Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110(6):1087-107. doi:10.1160/TH13-06-0443.De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis — Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110(6):1087-107. doi:10.1160/TH13-06-0443.Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84-91. doi:10.1161/CIRCOUTCOMES.108.796185.Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84-91. doi:10.1161/CIRCOUTCOMES.108.796185.Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335(8):540-6. doi:10.1056/NEJM199608223350802.Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335(8):540-6. doi:10.1056/NEJM199608223350802.Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrialfibrillation and implicationsfor the outcome of ablation: the ARREST-AF cohort study. J Am CollCardiol. 2014;64(21):2222-31. doi:10.1016/j.jacc.2014.09.028.Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrialfibrillation and implicationsfor the outcome of ablation: the ARREST-AF cohort study. J Am CollCardiol. 2014;64(21):2222-31. doi:10.1016/j.jacc.2014.09.028.Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factormanagementon symptom burden and severity in patients with atrial fibrillation: a randomizedclinical trial. JAMA. 2013;310(19):2050-60. doi:10.1001/jama.2013.280521.Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factormanagementon symptom burden and severity in patients with atrial fibrillation: a randomizedclinical trial. JAMA. 2013;310(19):2050-60. doi:10.1001/jama.2013.280521.Manolis AJ, Rosei EA, Coca A, et al. Hypertensionand atrial fibrillation: diagnostic approach, prevention and treatment. Position paperof the Working Group "Hypertension Arrhythmias and Thrombosis" of the European Society of Hypertension. J Hypertens. 2012;30(2):239-52. doi:10.1097/HJH.0b013e32834f03bf.Manolis AJ, Rosei EA, Coca A, et al. Hypertensionand atrial fibrillation: diagnostic approach, prevention and treatment. Position paperof the Working Group "Hypertension Arrhythmias and Thrombosis" of the European Society of Hypertension. J Hypertens. 2012;30(2):239-52. doi:10.1097/HJH.0b013e32834f03bf.Kotecha D, Chudasama R, Lane DA, et al. Atrial fibrillation and heart failure due to reduced versuspreserved ejection fraction: A systematic reviewand meta-analysis of death and adverse outcomes. Int J Cardiol. 2016;203:660-6. doi:10.1016/j.ijcard.2015.10.220.Kotecha D, Chudasama R, Lane DA, et al. Atrial fibrillation and heart failure due to reduced versuspreserved ejection fraction: A systematic reviewand meta-analysis of death and adverse outcomes. Int J Cardiol. 2016;203:660-6. doi:10.1016/j.ijcard.2015.10.220.Stewart S, Ball J, Horowitz JD, et al. Standard versus atrial fibrillation-specific managementstrategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet. 2015;385(9970):775- 84. doi:10.1016/S0140-6736(14)61992-9.Stewart S, Ball J, Horowitz JD, et al. Standard versus atrial fibrillation-specific managementstrategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet. 2015;385(9970):775- 84. doi:10.1016/S0140-6736(14)61992-9.An J, Niu F, Zheng C, et al. Warfarin Management and Outcomes in Patients with NonvalvularAtrial Fibrillation Within an Integrated Health Care System. J Manag Care Spec Pharm. 2017;23(6):700-12. doi:10.18553/jmcp.2017.23.6.700.An J, Niu F, Zheng C, et al. Warfarin Management and Outcomes in Patients with NonvalvularAtrial Fibrillation Within an Integrated Health Care System. J Manag Care Spec Pharm. 2017;23(6):700-12. doi:10.18553/jmcp.2017.23.6.700.Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi:10.1056/NEJMoa0905561.Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi:10.1056/NEJMoa0905561.Faust O, Ciaccio EJ, Acharya UR. A Review of Atrial Fibrillation Detection Methods as a Service. Int J Environ Res Public Health. 2020;17(9):3093. doi:10.3390/ijerph17093093.Faust O, Ciaccio EJ, Acharya UR. A Review of Atrial Fibrillation Detection Methods as a Service. Int J Environ Res Public Health. 2020;17(9):3093. doi:10.3390/ijerph17093093.Wynn GJ, Todd DM, Webber M, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014;16(7):965-72. doi:10.1093/europace/eut395.Wynn GJ, Todd DM, Webber M, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014;16(7):965-72. doi:10.1093/europace/eut395.Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrialfibrillation. N Engl J Med. 2013;369(22):2093-104. doi:10.1056/NEJMoa1310907.Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrialfibrillation. N Engl J Med. 2013;369(22):2093-104. doi:10.1056/NEJMoa1310907.Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improvesanticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One. 2013;8(9):e74037. doi:10.1371/journal.pone.0074037.Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improvesanticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One. 2013;8(9):e74037. doi:10.1371/journal.pone.0074037.Aliot E, Breithardt G, Brugada J, et al. Atrial Fibrillation AWareness and Risk Education group [comprising the Atrial Fibrillation Association (AFA), the European Heart Rhythm Association (EHRA), Stroke Alliance for Europe (SAFE), and the World Heart Federation (WHF)]. Aninternational survey of physician and patient understanding, perception, and attitudes to atrialfibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace. 2010;12:626-33.Aliot E, Breithardt G, Brugada J, et al. Atrial Fibrillation AWareness and Risk Education group [comprising the Atrial Fibrillation Association (AFA), the European Heart Rhythm Association (EHRA), Stroke Alliance for Europe (SAFE), and the World Heart Federation (WHF)]. Aninternational survey of physician and patient understanding, perception, and attitudes to atrialfibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace. 2010;12:626-33.Hohnloser SH, Crijns H, Jvan Eickels M, et al. Effect of dronedarone on cardiovascular events inatrial fibrillation. N Engl J Med. 2009;360(7):668-78. doi:10.1056/NEJMoa0803778.Hohnloser SH, Crijns H, Jvan Eickels M, et al. Effect of dronedarone on cardiovascular events inatrial fibrillation. N Engl J Med. 2009;360(7):668-78. doi:10.1056/NEJMoa0803778.Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю., Драпкина О.М. Разработка и валидизация новых опросников в медицине на примере шкалы приверженности лекарственной терапии. Рациональная Фармакотерапия в Кардиологии. 2021;17(4):576-83. doi:10.20996/1819-6446-2021-08-02.Lukina YuV, Kutishenko NP, Martsevich SYu, Drapkina OM. The Questionnaire Survey Method in Medicine on the Example of Treatment Adherence Scales. Rational Pharmacotherapy in Cardiology. 2021;17(4):576-83. (In Russ.) doi:10.20996/1819-6446-2021-08-02.

The authors declare that there are no conflicts of interest present.